品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

EagleBio/IFN Assay Type I Ready Cells/BM3049

价格
面议
货号:BM3049
浏览量:127
品牌:EagleBio
服务
全国联保
正品保证
正规发票
签订合同
商品描述

iLite Type I IFN Assay Ready Cells

IFN Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite Type IIFN Assay Ready Cells are intended for:

  • Quantification of interferon alpha or beta activity
  • Determination of Interferon alpha or beta NAbs

Content: iLite® Type I IFN Assay Ready Cells 1 vial (2.5mL)
Alternative Names: Type I Interferon Assay Ready Cells
For Research Use Only


Key benefits of iLite® Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (>10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Overview

In this product, human cells (U937, ATCC# CRL1593.2) engineered to express Firefly Luciferase under the control of an IFN α/β responsive promoter. When IFNα or IFNβ binds to the IFN α/β receptor on the cell surface, the IFN α/β regulated Firefly Luciferase reporter gene construct will be activated, resulting in a luminescent signal.


Principle

Interferon alpha (IFNα) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia and cutaneous T-cell lymphoma. Several different recombinant preparations of IFNα are available commercially; the most commonly used formulations include IFNα2a and IFNα2b. A number of studies have shown that development of anti-IFNα neutralizing antibodies (NAbs) is correlated with a loss of IFNα treatment efficacy. Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.


Products Related to IFN Assay Ready Cells

iLite Insulin Assay Ready Cells
iLite FGF-21 Assay Ready Cells
iLite IL-2 Assay Ready Cells

EagleBio的5α-雄甾烷-3α,17β-二醇葡糖醛酸化物是C19类固醇,缩写为3α-DiolG,5α二醇G或简称为α二醇G。它主要作为睾丸激素和二氢睾丸激素(DHT)的代谢产物生产。它主要在目标外围组织(例如皮肤)中产生,尤其是在毛囊周围。大量的3α-DiolG刺激会导致过多的头发形成,特别是在女性通常不存在头发的地方。近年来,在研究患有特发性多毛症的妇女的临床研究人员中,人们对这种类固醇的测量越来越感兴趣。已知是3α-DiolG前体的类固醇包括脱氢表雄酮(DHEA),硫酸脱氢表雄酮(DHEAS),二氢睾丸酮(DHT),雄烯二酮和睾丸激素。已显示只有3α-DiolG随多毛症增加而随治疗减少。这种相关性在多囊卵巢综合征(PCO)患者中也得到了证明。3α-DiolG的测定因此被证明是多种方式的有用指标,包括监测特发性多毛症和PCO妇女的治疗进展。此外,接受环孢霉素A治疗的糖尿病患者(无论男女)均显示3α-DiolG水平升高,这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标,包括监测特发性多毛症和PCO妇女的治疗进展。此外,接受环孢霉素A治疗的糖尿病患者(无论男女)均显示3α-DiolG水平升高,这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标,包括监测特发性多毛症和PCO妇女的治疗进展。此外,接受环孢霉素A治疗的糖尿病患者(无论男女)均显示3α-DiolG水平升高,这种副作用导致以前无毛的区域出现了头发。